<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05026203</url>
  </required_header>
  <id_info>
    <org_study_id>109/2564(IRB1)</org_study_id>
    <nct_id>NCT05026203</nct_id>
  </id_info>
  <brief_title>Effectiveness of Ketamine Treatment for Three Consecutive Days in Depression</brief_title>
  <official_title>Effectiveness of Ketamine Treatment in Difficult-to-treat Depression Comparing With Midazolam: a Double-blind Randomized Controlled Trial and Its Cost Effectiveness Analysis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mahidol University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mahidol University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Inclusion criteria: 1. patient over 20 years old with depression diagnosed by a psychiatrist&#xD;
      and MADRS &gt;= 25 scores; 2. failed to improve by at least optimal dosage of two&#xD;
      antidepressants for four weeks and one psychotherapy. Patients and outcome assessors will be&#xD;
      blinded from intervention the patients have.&#xD;
&#xD;
      Participants will be randomized into two groups that are intervention (ketamine 0.5 mg/kg IV&#xD;
      drip in 40 minutes) and control (midazolam 0.045 mg/kg IV drip in 40 minutes) groups.&#xD;
      Participants will administer ketamine/midazolam once daily for three consecutive days. They&#xD;
      will be evaluate MADRS changing, vital signs, dissociative symptoms, CGI, and quality of life&#xD;
      (EQ-5D-5L) during the treatment, at 1 week and 4 weeks after treatment completion.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 1, 2021</start_date>
  <completion_date type="Anticipated">June 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>depression scores</measure>
    <time_frame>1 month</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Depression</condition>
  <arm_group>
    <arm_group_label>Ketamine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Midazolam</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketamine Hydrochloride</intervention_name>
    <description>Ketamine hydrochloride 0.5 mg/kg intravenous administer in 40 minutes per day for 3 consecutive days</description>
    <arm_group_label>Ketamine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Midazolam</intervention_name>
    <description>Midazolam</description>
    <arm_group_label>Midazolam</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  over 20 years old&#xD;
&#xD;
          -  depression was diagnosed by a psychiatrist and having MADRS &gt;= 25&#xD;
&#xD;
          -  depression treated with 2 optimal dosage of antidepressants for 4 weeks and one&#xD;
             psychotherapy&#xD;
&#xD;
          -  stable dosage of current medications for 4 weeks&#xD;
&#xD;
          -  fluently Thai&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  secondary depression&#xD;
&#xD;
          -  PTSD&#xD;
&#xD;
          -  current pregnancy&#xD;
&#xD;
          -  history of increased intracranial hemorrhage, increased intracranial pressure, severe&#xD;
             head injury, abnormal thyroid function, angina, heart failure, arrhythmia, aneurysm,&#xD;
             uncontrolled hypertension, chronic lower tract respiratory disease, myasthenia gravis,&#xD;
             glaucoma, dementia, acute porphyria, or cystitic (within 3 months prior to&#xD;
             recruitment)&#xD;
&#xD;
          -  allergy to ketamine or midazolam&#xD;
&#xD;
          -  history of substance use disorder within 1 year prior to recruitment&#xD;
&#xD;
          -  history of psychosis within 3 months&#xD;
&#xD;
          -  history of bipolar disorder&#xD;
&#xD;
          -  BMI over 35&#xD;
&#xD;
          -  frail medical condition&#xD;
&#xD;
          -  currently ECT or TMS&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 24, 2021</study_first_submitted>
  <study_first_submitted_qc>August 27, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 30, 2021</study_first_posted>
  <last_update_submitted>August 27, 2021</last_update_submitted>
  <last_update_submitted_qc>August 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mahidol University</investigator_affiliation>
    <investigator_full_name>Keerati Pattanaseri</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Midazolam</mesh_term>
    <mesh_term>Ketamine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

